Cystic Fibrosis Therapeutics: The Road Ahead. Ahead of the Curve Seattle Children's Hospital and the University of Washington School of Medicine, Seattle, WA Received 29 June 2012, Accepted 6 July 2012, Available online 16 December 2015 Choose an option to locate/access this article: Check if you have access through your login credentials or your institution Check access Get rights and content A great deal of excitement and hope has followed the successful trials and US Food and Drug Administration approval of the drug ivacaftor (Kalydeco), the first therapy available that targets the underlying defect that causes cystic fibrosis (CF).
BTS/SIGN British guideline on the management of asthma | British Thoracic Society | Better lung health for all. Representatives from BTS, SIGN and NICE met in April 2018 to discuss the development of future asthma Guidelines. All three organisations have agreed to work together to develop a proposal for a single co-badged Guideline. Further details about the likely timeframe for the publication of any joint document will be available in due course as plans develop. In the interim BTS and SIGN will continue to work together to produce the next edition of the BTS/SIGN Guideline for the management of asthma which is due for publication in mid-2019. May 2018 NICE Guidelines for Asthma: diagnosis, monitoring and chronic asthma management have been published. BTS has produced a clinical response to the NICE Guidelines - available here. We hope this will be helpful to people with asthma, their carers and healthcare professionals. January 2018 BTS/SIGN asthma guideline 2019 BTS and SIGN are now working on the next update of the BTS/SIGN British guideline on the management of asthma.
Full guideline November 2016. (*NEW) 2016 Pocket Guide for Asthma Management and Prevention - Global Initiative for Asthma - GINA. Factors that may trigger or worsen asthma symptoms include viral infections, domestic or occupational allergens (e.g., house dust mite, pollens, cockroach), tobacco smoke, exercise and stress.
These responses are more likely when asthma is uncontrolled. Some drugs can induce or trigger asthma, e.g., beta-blockers, and (in some patients) aspirin or other NSAIDs. Asthma flare-ups (also called exacerbations or attacks) may occur, even in people taking asthma treatment. When asthma is uncontrolled, or in some high-risk patients, these episodes are more frequent and more severe, and may be fatal. A stepwise approach to treatment takes into account the effectiveness of available medications, their safety, and their cost to the payer or patient.
Regular controller treatment, particularly with inhaled corticosteroid (ICS)-containing medications, markedly reduces the frequency and severity of asthma symptoms and the risk of having a flare-up. Inhaler Technique Videos | Asthma Society of Ireland. Global Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD. Asthma, COPD, and Asthma-COPD Overlap Syndrome - Global Initiative for Chronic Obstructive Lung Disease - GOLD. GOLD documents are protected by copyright. A single copy of this document may be downloaded for your own educational use, but copies may not be made for distribution or posted on a website without authorization from GOLD. A significant proportion of adult patients over age 40 who present with symptoms of a chronic airways disease have features of both asthma and COPD. Several diagnostic terms, most including the word ‘overlap’, have been applied to such patients, and the topic has been extensively reviewed.
However, there is no generally agreed term or defining features for this category of chronic airflow limitation, although a definition based upon consensus has been published for overlap in patients with existing COPD. This document has been developed by the Science Committees of both GINA and GOLD, based on a detailed review of available literature and consensus.
1302. 871. 798. Clinical Review : Cystic fibrosis. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study -- Schuster et al. 68 (4): 344 -- Thorax. + Author Affiliations Correspondence to Dr Antje Schuster, Zentrum für Kinder und Jugendmedizin, Moorenstrasse 5, Düsseldorf 40225, Germany;firstname.lastname@example.org Received 17 April 2012 Accepted 11 October 2012 Published Online First 7 November 2012 Abstract Purpose To assess efficacy and safety of a new dry powder formulation of inhaled colistimethate sodium in patients with cystic fibrosis (CF) aged ≥6 years with chronic Pseudomonas aeruginosa lung infection. Study design and methods A prospective, centrally randomised, phase III, open-label study in patients with stable CF aged ≥6 years with chronic P aeruginosa lung infection.
Patients were randomised to Colobreathe dry powder for inhalation (CDPI, one capsule containing colistimethate sodium 1 662 500 IU, twice daily) or three 28-day cycles with twice-daily 300 mg/5 ml tobramycin inhaler solution (TIS). Results 380 patients were randomised. Trial Reg No EudraCT 2004-003675-36. Key messages What is the key question? Figure 1. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial - Journal of Cystic Fibrosis. Fig. 1 Study design (A) and disposition (B). Fig. 2 Overall efficacy: A) relative change in FEV1% predicted from baseline over three cycles (efficacy population); and B) change from baseline in Pseudomonas aeruginosa sputum density (efficacy population). Background A light-porous-particle, dry-powder formulation of tobramycin was developed, using PulmoSphere® technology, to improve airway delivery efficiency, substantially reduce delivery time, and improve patient convenience and satisfaction.
Methods In this open-label study, 553 patients were randomized 3:2 to TIP (total 112 mg tobramycin) via the Novartis T-326 Inhaler or TIS 300 mg/5 mL via PARI LC® PLUS nebulizer twice daily for three treatment cycles (28 days on-drug, 28 days off-drug). Results TIP was generally well-tolerated; adverse events were similar in both groups. Conclusions TIP has a safety and efficacy profile comparable with TIS, and offers a far more convenient treatment option for pseudomonas lung infection in CF. New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Associate editor: P. Molenaar a Department of Thoracic Medicine, Prince Charles Hospital, Brisbane, Australiab Queensland Children's Medical Research Institute, Brisbane, Australiac Pediatric Pulmonology, Department of Pediatrics, University of Leuven, Leuven, Belgiumd University of Lisboa, Faculty of Sciences, BioFIG — Centre for Biodiversity, Functional and Integrative Genomics, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal Available online 14 June 2014 Choose an option to locate/access this article: Check if you have access through your login credentials or your institution Check access Get rights and content Abstract With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced.
Keywords Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator protein; CFTR2; Correctors; Potentiators; Trial end-points Abbreviations Copyright © 2014 Elsevier Inc. Lumacaftor/ivacaftor combination therapy. CF Centres. Nebulised Levofloxacin (Quinsair tm) Drug Development Pipeline | CF Foundation. Orkambi, INN-lumacaftor & ivacaftor.